Given the well-defined pathogenic role of mutated BRAFV600 in melanoma, targeting this kinase and its substrate MEK1/2 has been in focus of several studies and clinical trials resulting in FDA-approved inhibitors such as vemurafenib, dabrafenib and encorafenib to block enhanced activity of mutated BRAF, and trametinib, binimetinib and cobimetinib to inhibit the activity of MEK1/2 [3,4,5]. This evidence concerns the gene BRAF and melanoma.